Ras and seppuku in neuroblastoma

Journal of the National Cancer Institute

Volumn 94, Issue 5, 2002, Pages 319-321

  Reynolds, C Patrick ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CATECHOLAMINE; DNA; DNA NUCLEOTIDYLEXOTRANSFERASE; ISOTRETINOIN; LIGAND; MYELOABLATIVE AGENT; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIN RECEPTOR; PROTEIN P53; RAS PROTEIN; TELOMERASE; TUMOR MARKER;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DEGENERATION; CHILDHOOD CANCER; CONTROLLED STUDY; EDITORIAL; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC TRANSFECTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; NEUROBLAST; NEUROBLASTOMA; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; TUMOR LOCALIZATION;

EID: 0037029099     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.5.319     Document Type: Editorial

References (43)

1. Neuroblastoma
2. Spontaneous regression of cancer
3. Spontaneous regression of an untreated neuroblastoma
4. Spontaneous regression of neuroblastoma
5. The spontaneous regression of neuroblastoma. Experimental evidence for a natural host immunity
6. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment
7. Neuroblastoma stage IV-S
8. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study
9. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study
10. The natural history of neuroblastic cells in the fetal adrenal gland
11. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy
12. Neuroblastoma: Epidemiology and pattern of regression. Problems in interpreting results of mass screening
13. Observation of untreated patients with neuroblastoma detected by mass screening: A "wait and see" pilot study
14. Clinicopathologic study of mass-screened neuroblastoma with special emphasis on untreated observed cases: A possible histologic clue to tumor regression
15. A trial to discriminate spontaneous regression from non-regression cases during mass screening for neuroblastoma
16. The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma
17. Maturation of sympathicoblastoma into ganglioneuroma
18. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
19. Immunity to tumor antigens: Potential implications in human neuroblastoma
20. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells
21. Correlating telomerase activity levels with human neuroblastoma outcomes
22. Telomerase as a biological and prognostic marker in neuroblastoma
23. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells
24. In situ detection of DNA fragmentation and expression of bcl-2 in human neuroblastoma: Relation to apoptosis and spontaneous regression
25. Demonstration of apoptosis in neuroblastoma and its relationship to tumour regression
26. Cellular death in neuroblastoma: In situ correlation of apoptosis and bcl-2 expression
27. Evidence of apoptosis in neuroblastoma at onset and relapse. An analysis of a large series of tumors
28. Increased Ras expression and caspase-indenpendent neuroblastoma cell death: Possible mechanism of spontaneous neuroblastoma regression
29. A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases
30. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: A comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening
31. The NGF story and neuroblastoma
32. Ras regulates sympathetic neuron survival by suppressing the p53-mediated cell death pathway
33. Caspase-independent programmed cell death with necrotic morphology
34. More than one way to die: Apoptosis, necrosis and reactive oxygen damage
35. Caspase regulation of neuronal progenitor cell apoptosis
36. Msx-2 and p21 mediate the pro-apoptotic but not the anti-proliferative effects of BMP4 on cultured sympathetic neuroblasts
37. Induction of apoptosis by p75 neurotrophin receptor in human neuroblastoma cells
38. Molecular biology of neuroblastoma
39. Apoptosis and cancer chemotherapy
40. Induction of apoptosis by cancer chemotherapy
41. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines
42. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines
43. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism